

14. ULUSAL AFEREZ
KONGRESİ
22-23 KASIM 2019 MARriot ASIA HOTEL , İSTANBUL



TERAPÖTİK PLAZMA DEĞİŞİMİ: 7 YILLIK TEK MERKEZ DENEYİMİ

Dr. Seval AKPINAR

NAMIK KEMAL ÜNİVERSİTESİ İÇ HASTALIKLARI AD-HEMATOLOJİ BD

23 KASIM 2019 - İSTANBUL

Çalışma künyesi


- ✓ Geriye dönük, tek merkezli
- ✓ Primer amaç: TPE uygulamalarımızın yıllar içindeki değişiminin değerlendirilmesi
- ✓ Dönem: Ocak 2012-Ekim 2019
- ✓ TPE uygulanan ardışık tüm hastalar
- ✓ Tanımlayıcı istatistik
- ✓ TPE endikasyonlarının kategorik değerlendirmesi: ASFA-2019

Demografik ve klinik veriler

- ✓ n: 63
- ✓ Erkek (n: 26); kadın (n: 37)
- ✓ Yaş (medyan; aralık): 56 (18-83)
- ✓ TPE seans sayısı (medyan; aralık): 3 (1-25)


TPE ENDİKASYONLARI

■ Hematolojik ■ Nörolojik ■ Romatolojik ■ Endokrinolojik




REPLASMAN SIVISI


■ TDP ■ ALBUMIN



ENDİKASYONLAR: ASFA-2019



TPE AKTİVİTESİ: 2012-2019



Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue


**Anand Padmanabhan¹ | Laura Connelly-Smith² | Nicole Aqui³ | Rasheed A. Balogun⁴ |
Reinhard Klingel⁵ | Erin Meyer⁶ | Huy P. Pham⁷ | Jennifer Schneiderman⁸ |
Volker Witt⁹ | Yanyun Wu¹⁰ | Nicole D. Zantek¹¹ | Nancy M. Dunbar¹² |**

Guest Editor: Joseph Schwartz¹³

Endikasyonların sınıflaması

Category	Description
I	Disorders for which apheresis is accepted as first-line therapy, either as a primary standalone treatment or in conjunction with other modes of treatment.
II	Disorders for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other modes of treatment.
III	Optimum role of apheresis therapy is not established. Decision making should be individualized.
IV	Disorders in which published evidence demonstrates or suggests apheresis to be ineffective or harmful. IRB approval is desirable if apheresis treatment is undertaken in these circumstances.

Endikasyonların dağılımı



The number and activity of TACs in Turkey between 1998 and 2014

	1998 [4]	2011 [5]	2014 ^b
TACs (n)	31	53	71
Education Centers (n)	–	4 ^b	12
TAPs (n)	1073	12000	26344
HPC ^a apheresis (n)	1126	2294	4540

2018 yılında ulusal TPE aktivitesi

2019 yılında toplam TAM: 78

TPE	22873
ECP	5912
AUTO-HSC COLLECTION	4706
ALLO-HSC COLLECTION	2109
LIPID APHERESIS	2016
CASCADE FILTRATION	1021
LEUCOCYTAPHERESIS	1007
ERITROCYTAPHERESIS	928
IMMUNADSORBTION	519
GRANULOCYTAPHERESIS	511
THROMBOCYTAPHERESIS	23
TOTAL	41625

The Turkish experience with therapeutic plasma exchange: A national survey

Serdal Korkmaz^{a,*}, Serife Solmaz Medeni^b, Fatih Demirkan^c, Sevgi Kalayoglu Besisik^d, Senem Altay Dadin^d, Gulsum Akgun Cagliyan^e, Sibel Kabukcu Hacioglu^e, Ismail Sari^e, Deniz Goren Sahin^{f,g}, Mutlu Arat^g, Simten Dagdas^h, Gulsum Ozet^h, Nermin Kutluⁱ, Tulay Karaagac Akyolⁱ, Osman Ilhami Ozcebe^j, Hava Uskudar Teke^k, Demet Kiper Unal^l, Naile Guner^l, Anil Tombak^m, Halil Celikⁿ, Ilker Bay^o, Ilhami Kiki^o, Gokhan Ozgur^p, Mehmet Ali Erkurt^q, Duzgun Ozatli^r, Ozgur Meletli^r, Sinan Demircioglu^s, Cengiz Demir^s, Erdal Kurtoglu^t, Filiz Vural^u, Mahmut Tobu^u, Abdullah Karakus^v, Orhan Ayyildiz^v, Mehmet Sinan Dal^w, Berna Afacan Ozturk^x, Murat Albayrak^x, Serkan Ocakci^y, Zahit Bolaman^z, Mehmet Sonmez^A, Volkan Karakus^B, Omur Gokmen Sevindik^C, Ilhami Berber^D, Mehmet Hilmi Dogu^E, Emine Gulturk^F, Turgay Ulas^G, Bahriye Payzin^l, Irfan Kuku^q, Seckin Cagiran^z, Fevzi Altuntas^{w,H}

TPE: Ulusal veri

- > 16 yaş
- Ocak 2007-Aralık 2017
- Retrospektif
- Merkez sayısı:28
- TPE işlem sayısı: 24912
- Hasta sayısı: 3203

The technical notes of therapeutic plasma exchange procedures.

Parameters	Values
Total number of patients, female to male	3203 (1623/1580)
Five most indications, n (%)	
- Thrombotic thrombocytopenic purpura	502 (15.7)
- Renal transplantation, ABO incompatible	390 (12.2)
- Hyperviscosity in monoclonal gammopathies	289 (9.0)
- Myasthenia gravis	210 (6.6)
- Guillain-Barre syndrome	174 (5.4)
Total number of procedures	24912
Number of procedures per patient, median (range; min-max)	5 (1-100)
Duration of procedure (minutes), median (range; min-max)	100 (16-450)
Frequency of procedure, n (%)	
- Daily	1782 (55.6)
- Every other day	1183 (36.9)
- Once a week	57 (1.8)
- Twice weekly	58 (1.8)
- Three times a week	47 (1.5)
- Other	76 (2.3)
Plasma volume treated (x PV), n (%)	
- 1	2131 (66.5)
- 1.5	998 (30.8)
- 2	84 (2.6)
Venous access, n (%)	
- Peripheral vein	508 (15.9)
- Central venous catheter	2607 (81.4)
- Arterio-venous fistula	88 (2.7)
Anticoagulant, n (%)	
- ACD-A	1671 (52.2)
- Heparin	368 (11.5)
- Heparin / ACD-A	1164 (36.3)
Replacement fluid, n (%)	
- FFP (fresh frozen plasma)	1856 (57.9)
- 5% Albumin	1109 (34.6)
- HES (hydroxyethyl starch)	31 (1.0)
- HES plus 5% Albumin	1 (0.0)
- FFP plus 5% Albumin	206 (6.4)
- SDP (solvent detergent plasma)	0 (0.0)
Apheresis device*	Spectra Optia / Fresenius
Responses, n (%)	
- Complete remission	1973 (61.6)
- Partial remission	718 (22.4)
- No response	512 (16.0)

Yanit

Patient population	Number of patients	Number of procedures	ASFA 2016 category	CR n (%)	PR n (%)	No response n (%)
Neurological diseases						
-Myasthenia gravis	210	1451	I	141 (67.1)	46 (21.9)	23 (11)
-Guillain-Barre syndrome	174	975	I	122 (70.1)	35 (20.1)	17 (9.8)
-Neuromyelitis optica spectrum disorders	69	421	II	46 (66.7)	17 (24.6)	6 (8.7)
-Chronic inflammatory demyelinating polyradiculoneuropathy	15	92	I	9 (60)	6 (40)	0 (0.0)
Hematologic diseases						
-Thrombotic thrombocytopenic purpura	502	7973	I	385 (76.7)	39 (7.8)	78 (15.5)
-Hyperviscosity in monoclonal gammopathies	289	1434	I	190 (65.7)	76 (26.3)	23 (8)
-Myeloma cast nephropathy	55	219	II	33 (60)	19 (34.5)	3 (5.5)
-Hematopoietic stem cell transplantation, ABO Incompatible	37	73	II	36 (97.3)	1 (2.7)	0 (0.0)
-Severe cold agglutinin disease	26	136	II	19 (73.1)	6 (23.1)	1 (3.8)
-Autoimmune hemolytic anemia; WAIHA	12	65	III	8 (66.7)	2 (16.7)	2 (16.7)
-Thrombotic microangiopathy, drug associated	8	109	I / III	5 (62.5)	3 (37.5)	0 (0.0)
Renal diseases						
-Renal transplantation, ABO incompatible	390	2405	I / II	269 (69)	85 (21.8)	36 (9.2)
- Focal segmental glomerulosclerosis	55	429	I	41 (74.5)	11 (20.0)	3 (5.5)
-Goodpasture's syndrome	26	248	I	16 (61.5)	1 (3.8)	9 (34.7)
Rheumatic diseases						
-Vasculitis	93	717	II / III	56 (60.2)	19 (20.4)	18 (19.4)
-Systemic lupus erythematosus	64	433	II	39 (60.9)	15 (23.4)	10 (15.7)





Fig. 1. The distribution of the patients and TPE procedures by year.

TPE Endikasyonları



TPE aktivitesi eğilimi

